๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
AlzeCure Pharma AB (publ) (STO:ALZCUR)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
5.68
-0.16 (-2.74%)
Nov 20, 2026, 5:29 PM CET
โ† View all transcripts

BioStock Life Science Summit 2026

Nov 4, 2026

Summary

Two global licensing deals for Alzstatin and NeuroRestore totaled $3.2B, excluding royalties, and strengthened the financial position. Focus is shifting to partner collaborations and advancing ACD137 and ACD440, including ACD440's next erythromelalgia stage.

Johan Sandin
Interim CEO, AlzeCure Pharma

Here to present AlzeCure Pharma here today. As a company, we are focusing on developing novel therapies for Alzheimer's disease and pain, areas of huge unmet medical need. As a company, we're a spin-out from AstraZeneca, and we are based at Karolinska Institutet in Stockholm. We're working with three small molecule project platforms, two within Alzheimer's disease, Alzstatin, which is a disease-modifying agent for Alzheimer's disease, and NeuroRestore, which is a cognitive enhancer, but also has antidepressant effect. Both of these programs have been out-licensed during the summer, and I'll come back to that later on. We also have a Painless platform with two assets, ACD137, which is in preclinical stage, and ACD440, which is in phase II.

We are also a public company since 2018, and we have a stable cash position based on the out-licensing deals we've done, and also a rights issue which we conducted during the summer. We also received an EIC grant for one of our programs. As a company, we're a research and development company focusing on developing our assets up to early clinical phase, up to phase II primarily. A business model that's now been validated through the two out-licensing deals that we've made this summer. This is our current pipeline. As you can see on top here, we have the NeuroRestore program with ACD856 being the lead molecule. This has shown positive phase I data, and this is again targeting NGF and BDNF signaling, so neurotrophin signaling, which plays a critical role in both neuronal function, but also cognitive function.

It's also been shown to play a really important role in depression. This has been out-licensed to QuantumCell during the summer. Then we also have the Alzstatin program, which is a disease-modifying agent, so-called gamma-secretase modulator targeting amyloid accumulation in the brain. Again, this program has been out-licensed to Eli Lilly this year. Then we also have two pain assets, ACD137, which is a negative allosteric modulator of NGF signaling. This is again in preclinical stage. Then we have a phase II asset, ACD440, which is a TRPV1 antagonist targeting both neuropathic pain, but also in rare disorders. So 2026 has really been the transformational year for the company, obviously with the two out-licensing deals as the real highlights of the year. But we've also produced positive clinical data for the programs.

We have had regulatory interactions which have resulted in orphan drug designation for ACD440, and we've also strengthened the balance sheet for the company. So the two deals, as I mentioned, were for Alzstatin, the gamma-secretase modulator with Lilly, as well as the NeuroRestore program for QuantumCell. These two deals have a combined deal value of $ 3.2 billion, excluding royalties. Both of them are out-licensing and collaboration deals with global rights, and we received upfront for both programs. Turning to our Painless platforms, which we still have and are working on internally, we have the ACD137, which is targeting osteoarthritis, a huge patient population with more than 300 million patients. We also have ACD440, which is a topical TRPV1 antagonist targeting neuropathic pain, but also rare disorders, again, with a huge patient population with regard to neuropathic pain. We start with ACD137.

This is a non-opioid treatment for osteoarthritis. This is targeting NGF signaling, which has a very strong both preclinically and clinical validation in pain, not the least from the anti-NGF antibodies, which were in late-stage clinical development, showing a really step change in efficacy, but with related side effects. This is a much more specific mechanism we're using here, specifically targeting TrkA signaling, thereby retaining analgesic efficacy, but avoiding the side effects. We've also shown in preclinical studies that we have at least as good analgesic efficacy as the NGF antibodies, but also we strengthen the joint and avoid degradation of the joint. This also has the advantage of being an oral treatment, so it's very convenient to take. Again, the compound has shown extremely good selectivity, which is really important for this mechanism of action. It's also highly potent.

Interesting to note is that Asahi Kasei, which has an asset in this area as well, that has shown positive clinical phase II data and is actually entering phase IIb. Our molecule is more selective, which is certainly key and a key differentiator from their compound. We also have ACD440, which is a TRPV1 antagonist. The TRPV1 receptor received the Nobel Prize in Medicine in 2021, the discoverer of it. It plays a key role in pain signaling, and this is a compound that was originally developed in big pharma as an oral treatment. We have reformulated it into a topical treatment for the treatment of peripheral pain disorders, and we conducted both phase Ib and phase IIa studies with positive data. This just shows the positive phase IIa results for ACD440, where we have treated patients with peripheral neuropathic pain.

These are chronic pain patients, and they were on concomitant treatment as well, including opioids, and we still had a 50% reduction in pain. So it was also well tolerated. We see this compound has a really interesting opportunity, not only in peripheral neuropathic pain, but also in rare disorders, and in this specific case, in erythromelalgia. Erythromelalgia is a rare disorder, about 13 out of 100,000. It's a chronic disorder that affects from the age of four and upwards. We have here received orphan drug designation both from EMA and FDA, and we have also received positive FDA feedback on a potential pivotal phase II/III clinical trial. What's the continued focus for the company? Obviously, the collaborations we have with Eli Lilly and QuantumCell remains the priority. That's something we're working on with them.

It's a collaboration deal, as I mentioned, so it's really important key for us to deliver and make sure that ACD856 and the NeuroRestore program, as well as ACD680 and the Alzstatin program, get the best and optimal way forward. We are also increasing our activities in the Painless programs, including ACD137, driving that towards clinical development, and ACD440. Here, again, we are preparing it for the next stage in erythromelalgia. Continued work on the business development side, obviously, with the two out-licensing deals, I think certainly validates our efforts there. Some key investment highlights from our side. We have conducted this year two major out-licensing agreements, certainly validating the company and the projects, as well as the team, with a combined deal value of $ 3.2 billion and excluding royalties.

We have also strengthened the financial position, both based on the out-licensing deals, but also with the rights issue. We have several additional value drivers still within the company, including our pain platform, Painless, containing both ACD137 and ACD440, which are both first in class. We are also targeting areas of significant unmet medical need with huge market potential. We have a proven business model with the two out-licensing deals certainly being the highlights and taking projects from ideas into out-licensing. With that, thank you very much, and I will take any questions.

Operator

Do we have any questions in the room? No. Let us start by addressing the fact that you very recently became the Interim CEO, and you are, of course, looking for a new CEO. Where are you in that process, and what sort of person are you looking for?

Johan Sandin
Interim CEO, AlzeCure Pharma

Well, that is, I guess, I mean, you are very true. I mean, I am just the Interim CEO at this point in time. But I have been CEO for the company since before and also one of the founders of the company. I think that is certainly more of a question to the board, I would say, at this point in time. But we are in a different stage now. We have certainly had a huge focus on the business development side, trying to out-license the programs, and we have succeeded twice this year. I think now we can have a bit more focus on driving the collaborations, which are clearly scientific collaborations with our partnered companies. Also, the scientific development and drug discovery development of the TrkA-NAM program and the ACD440 program. So it is a slight shift in focus.

Operator

In focus there.

Johan Sandin
Interim CEO, AlzeCure Pharma

Yes. I would say that is.

Operator

I have a question here about those deals. When can shareholders expect the first milestone payment?

Johan Sandin
Interim CEO, AlzeCure Pharma

That is always a key question.

Operator

That is a million-dollar question.

Johan Sandin
Interim CEO, AlzeCure Pharma

Exactly.

Operator

Quite literally, yeah.

Johan Sandin
Interim CEO, AlzeCure Pharma

Although we can't comment on the specific timing of that, I think, I mean, I can just confer that we are working really intensively trying to drive the development of programs within our two collaborators' facilities. I mean, clearly, both Lilly, I mean, hugely experienced in the area. I mean, you can't expect a better partner and the quickest way to get to the next milestone. I think we're really happy there.

Operator

I have a question here, and I hope I pronounce this correctly. With Asahi Kasei's phase IIb readout-

Johan Sandin
Interim CEO, AlzeCure Pharma

Yeah

Operator

-expected this year, how important could positive results be for the validation and partnering potential of your ACD137?

Johan Sandin
Interim CEO, AlzeCure Pharma

I think that certainly helps the program. I mean, we clearly see a differentiating part as well. Our compound is much more selective. It doesn't pass the BBB, blood-brain barrier, so it's a peripherally restricted compound, which is also really important from a side effect profile. We can see clear differentiators, but a positive result obviously certainly validates the program. I think another part is that the out-licensing deals per se also validates us as a company, as a team, and also our projects, which certainly helps.

Operator

Well, thank you so much, Johan.

Johan Sandin
Interim CEO, AlzeCure Pharma

Thank you very much.